Cross-sectional study on comorbidities and adverse events in @entity1 with advanced and recurrent XXXX in France.

@entity1 @entity43 @entity417 @entity146 @entity10 @entity204 @entity902
PURPOSE: The purpose of this study was to evaluate the prevalence of comorbidities and adverse events (AEs), and determine the treatment patterns according to @entity902 -sensitivity status in @entity1 with advanced (stage IIIB-IV) or recurrent @entity43 ( @entity43 ). METHODS: A cross-sectional study was carried out in France with @entity1 over 18 years, diagnosed with advanced (stage IIIB-IV) or recurrent @entity43 between 2009 and 2012. A total of 23 physicians (oncologists and gynecologists) participated, contributing 127 @entity1 . Data were abstracted by participating physicians into a case report form. RESULTS: Of the 127 @entity1 included, 92 (72.4%) had advanced @entity43 and 35 (27.6%) had recurrent @entity43 . A total of 73 comorbidities were reported in 44 @entity1 (34.6%). Vascular (10.2%), metabolic (7.1%), respiratory (5.5%), and @entity146 (5.5%) were the most common types of comorbidities reported. Prevalence of AEs was 74.8%, of which 12.6% were classified as serious. The most common AEs were @entity417 (16.5%), hematologic events (12.6%), taste change (11.8%), and @entity10 (7.1%). Throughout the follow-up period, twelve @entity1 @entity204 were reported (six due to disease progression). Of 35 @entity1 with recurrent disease, 16 were highly @entity902 sensitive (recurrence >12 months after stopping @entity902 -based therapy), eleven were partially @entity902 sensitive (recurrence 6-12 months after stopping @entity902 -based therapy), seven were @entity902 resistant (recurrence within 6 months of stopping @entity902 -based therapy or progression while receiving second- or later-line @entity902 -based therapy), and one was @entity902 refractory (recurrence within 6 months from the start of first-line @entity902 -based therapy). CONCLUSION: In this cross-sectional study of advanced and metastatic @entity43 @entity1 , approximately one-third of @entity1 were diagnosed with comorbidities, and approximately three-quarters were diagnosed with AEs (12.6% with severe AEs).
